Vanda Pharmaceuticals won FDA approval for Nereus, an oral treatment the company says is the first new medicine for motion sickness in more than four decades. The approval clears the way for a commercial launch in the coming months and expands Vanda’s product portfolio beyond its specialty neurology and sleep franchises. Regulatory context: the FDA approval follows submission of clinical efficacy and safety data supporting symptomatic relief of motion sickness. For clinicians: motion‑sickness indications typically require demonstration of symptom reduction in provoked challenge models or field studies. Why it matters: the approval opens a modest but longstanding unmet market and demonstrates the FDA’s willingness to greenlight incremental innovations in symptomatic indications, offering Vanda a near‑term revenue catalyst.